A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
← catalyst calendarNCT07023731 · readout in 103 d
Sponsored by Arvinas Inc. (industry) · ARVN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
159estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-29 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- KRAS G12D Mutation
- Advanced Solid Cancer
Intervention
- Drug: ARV-806
Primary outcomes
what the primary-completion date above is the date OFPart A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806
measured 28 days from first ARV-806 administration
Part A (Phase 1): Number of participants with AEs
measured From the study baseline to at least 28 days after last dose of ARV-806
Part B (Phase 2): Overall Response Rate (ORR)
measured Approximately 2 years
Permalink · ARVN's whole pipeline · Catalyst calendar · Every registered study · What changed